2023
Treatment options for necrobiosis lipoidica: a systematic review
Nihal A, Caplan A, Rosenbach M, Damsky W, Mangold A, Shields B. Treatment options for necrobiosis lipoidica: a systematic review. International Journal Of Dermatology 2023, 62: 1529-1537. PMID: 37772666, DOI: 10.1111/ijd.16856.Peer-Reviewed Original ResearchMeSH KeywordsCalcineurin InhibitorsGlucocorticoidsHumansJanus Kinase InhibitorsNecrobiosis LipoidicaRetrospective StudiesConceptsTopical calcineurin inhibitorsNecrobiosis lipoidicaTopical corticosteroidsCalcineurin inhibitorsTreatment optionsCase reportJAK inhibitorsSystematic reviewTreatment of NLLimited high-quality evidenceHigh-quality evidenceHigh morbidityCombination therapyRecalcitrant diseaseTreatment modalitiesCompression therapyStandardized endpointsTherapeutic modalitiesClinical careCollagen degenerationTreatment efficacyNew treatmentsLiterature searchTherapyCorticosteroidsBaseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis
Singh K, Valido K, Swallow M, Okifo K, Wang A, Cohen J, Damsky W. Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis. Journal Of The American Academy Of Dermatology 2023, 88: 1094-1100. PMID: 36780951, DOI: 10.1016/j.jaad.2022.12.052.Peer-Reviewed Original ResearchConceptsEczematous dermatitisHistologic featuresTreatment selectionType 1Type 3 inflammationInflammatory skin diseaseCertain histologic featuresSitu hybridization correlatesClinical responseNonresponder groupCytokine profileCytokine stainingAtopic dermatitisCytokine RNAEczematous disordersSitu hybridizationDupilumabIL13 expressionSkin diseasesType 2PatientsDermatitisNonrespondersMolecular heterogeneityImproved response
2022
Lack of association between pandemic chilblains and SARS-CoV-2 infection
Gehlhausen JR, Little AJ, Ko CJ, Emmenegger M, Lucas C, Wong P, Klein J, Lu P, Mao T, Jaycox J, Wang E, Ugwu N, Muenker C, Mekael D, Klein R, Patrignelli R, Antaya R, McNiff J, Damsky W, Kamath K, Shon J, Ring A, Yildirim I, Omer S, Ko A, Aguzzi A, Iwasaki A, Obaid A, Lu-Culligan A, Nelson A, Brito A, Nunez A, Martin A, Watkins A, Geng B, Kalinich C, Harden C, Todeasa C, Jensen C, Kim D, McDonald D, Shepard D, Courchaine E, White E, Song E, Silva E, Kudo E, DeIuliis G, Rahming H, Park H, Matos I, Nouws J, Valdez J, Fauver J, Lim J, Rose K, Anastasio K, Brower K, Glick L, Sharma L, Sewanan L, Knaggs L, Minasyan M, Batsu M, Petrone M, Kuang M, Nakahata M, Campbell M, Linehan M, Askenase M, Simonov M, Smolgovsky M, Sonnert N, Naushad N, Vijayakumar P, Martinello R, Datta R, Handoko R, Bermejo S, Prophet S, Bickerton S, Velazquez S, Alpert T, Rice T, Khoury-Hanold W, Peng X, Yang Y, Cao Y, Strong Y. Lack of association between pandemic chilblains and SARS-CoV-2 infection. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2122090119. PMID: 35217624, PMCID: PMC8892496, DOI: 10.1073/pnas.2122090119.Peer-Reviewed Original ResearchMeSH KeywordsAdultChilblainsConnecticutCOVID-19FemaleHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2Young AdultConceptsSARS-CoV-2 infectionPrior SARS-CoV-2 infectionSARS-CoV-2PC biopsiesAcute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemicT-cell receptor sequencingCell receptor sequencingT cell responsesCoronavirus 2 pandemicEnzyme-linked immunosorbent assayLack of associationCOVID toesSkin eruptionAntibody responseImmunohistochemistry studiesBackground seroprevalenceTissue microarrayViral infectionStimulation assaysCell responsesInfectionChilblainsImmunosorbent assayAbortive infection